

K070273  
Page 1 of 2

**VII. 510(k) Summary**

In accordance with Title 21 of the Code of Federal Regulations, Part 807, and in particular §807.92, the following summary of information is provided:

**A. Submitted by**

Laetitia Cousin  
Director of Regulatory Affairs and Quality Assurance  
NuVasive, Incorporated  
4545 Towne Centre Court  
San Diego, California 92121  
Telephone: (858) 909-1868  
Fax: (858) 909-2068

APR - 3 2007

**B. Device Name**

Trade or Proprietary Name: *NuVasive Lateral Plate System*  
Common or Usual Name: Spinal Implants  
Classification Name: Spinal Intervertebral Body Fixation orthosis.  
Device Class: Class II  
Classification: §888.3060  
Product Code: KWQ

**C. Predicate Devices**

The subject device is substantially equivalent to similar previously cleared devices.

**D. Device Description**

The *NuVasive Lateral Plate System* consists of a variety of plates, screws, bolts, and locking nuts. Implant components can be rigidly locked to suit the individual pathology and anatomical conditions of the patient.

**E. Intended Use**

The *NuVasive Lateral Plate System* is indicated for use via the lateral or anterolateral surgical approach above the bifurcation of the great vessels in the treatment of thoracic and thoracolumbar (T1-L5) spine instability or via the anterior surgical approach, below the bifurcation of the great vessels in the treatment of lumbar and lumbosacral (L1-S1) spine instability as a result of fracture (including dislocation and subluxation), tumor, degenerative disc disease (defined as back pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies), scoliosis, kyphosis, lordosis, spinal stenosis, or a failed previous spine surgery.

K070273  
Page 2 of 2

**F. Substantial Equivalence**

Data was provided which demonstrated the NuVasive Lateral Plate to be substantially equivalent to previously cleared devices. The substantial equivalence is based upon equivalence in indications for use, design, material, and function.

**G. Summary of Non-Clinical Tests**

Mechanical testing was presented.

**H. Summary of Clinical Tests**

(Not Applicable).



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

NuVasive, Incorporated  
c/o Ms. Laetitia Cousin  
Director of Regulatory Affairs and Quality Assurance  
4545 Towne Centre Court  
San Diego, California 92121

APR - 3 2007

Re: K070273  
Trade/Device Name: Nuvasive Lateral Plate System  
Regulation Number: 21 CFR §888.3060  
Regulation Name: Spinal Intervertebral Body Fixation Orthosis  
Regulatory Class: Class II  
Product Code: KWQ  
Dated: March 02, 2007  
Received: March 05, 2007

Dear Ms. Cousin:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

Handwritten signature of Barbara Melkerson in cursive script.

for  
Mark N. Melkerson  
Director  
Division of General, Restorative and  
Neurological Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

**Indications for Use**

510(k) Number (if known): K0 70273

Device Name: Lateral Plate System

Indications For Use:

*The NuVasive Lateral Plate System is indicated for use via a lateral or anterolateral surgical approach above the bifurcation of the great vessels in the treatment of thoracic and thoracolumbar (T1-L5) spine instability or via the anterior surgical approach, below the bifurcation of the great vessels in the treatment of lumbar and lumbosacral (L1-S1) spine instability as a result of fracture (including dislocation and subluxation), tumor, degenerative disc disease (defined as back pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies), scoliosis, kyphosis, lordosis, spinal stenosis, or a failed previous spine surgery.*

Prescription Use    
 (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use \_\_\_\_\_   
 (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

Page 1 of 1



**(Division Sign-Off)**

**Division of General, Restorative  
and Neurological Devices**

**510(k) Number** K070273